Strategic Capital to Advance Innovative Medicines
We provide strategic capital to advance innovative medicines.
Investing Across Biopharma
Ligand is a leading royalty aggregator that partners with biopharmaceutical companies to finance and advance late-stage clinical development programs. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 200 commercial, clinical and preclinical-stage programs.
Diversified Royalty Portfolio
Our portfolio spans multiple therapeutic areas, development stages, modalities, and partners, creating diversified exposure to innovative medicines that improve and extend lives worldwide.
By the Numbers
portfolio
assets
assets
0
+
marketed products generating royalties
0
+
key commercial-stage royalty streams
0
All figures as of July 14, 2026, unless otherwise indicated.
Ligand Completes XOMA Royalty Acquisition
Transaction adds seven commercial products and more than 100 additional programs, creating one of the largest portfolios of biopharma royalty assets.
Ligand Closes $700 Million Convertible Senior Notes Offering
Opportunistic capital raise enhances Ligand’s financial flexibility. and ability to invest in complementary businesses, companies, products, and technologies.
Travere Receives Full FDA Approval for FILSPARI® in FSGS
FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS, and Ligand is entitled to a 9% royalty on worldwide net sales.
Latest News
[wp-rss-aggregator template="default"]